NEOGENOMICS INC

NEO

Held by 2 specialist biotech funds

Share on X

Fund Holdings

Driehaus Capital Deerfield Management

AI Signal

AI analyst context — unlock full analysis

Catalysts

No catalysts tracked.

Position Details

Driehaus CapitalNEWFeb 17, 2026

Shares: 2,471,738Value: $29.1M

# Signal Note: Driehaus Capital Initiates NEO Position Growth-focused Driehaus Capital's $29.1M entry into Neo Genomics suggests confidence in the company's cancer genomics testing franchise, likely driven by expanding adoption of its solid tumor and blood-based liquid biopsy panels in oncology. The timing may reflect anticipated revenue acceleration from increased clinical utilization post-pandemic normalization and potential margin expansion as the company scales its proprietary testing platform.

Deerfield ManagementNEW

More NEO Analysis

Insider buy/sell details with names, titles, and amounts
AI-generated context for every signal

Start 7-Day Free Trial — $29/mo

Insider Signals

No insider signals tracked.

Also Held by These Funds

TNDM2 funds NUVL2 funds VEEV2 funds VCYT2 funds PODD2 funds NBIX2 funds BBNX2 funds TMDX

Research Links

Yahoo Finance →SEC EDGAR →ClinicalTrials.gov →

Track specialist biotech funds, insider signals, and AI analysis

Start 7-Day Free Trial

Or get the free weekly brief:

# Signal Note: Deerfield Management Initiates $64.7M Position in NeoGenomics Deerfield's significant entry into NEO signals conviction in the clinical lab testing and oncology genomics space, likely driven by confidence in NeoGenomics' cancer diagnostics growth trajectory and potential M&A consolidation opportunities within precision oncology. The $64.7M stake represents a meaningful conviction bet from a healthcare-focused multi-strategy fund with track record in identifying undervalued biotech assets. Near-term catalysts to monitor include quarterly revenue trends in their solid tumor and hematologic malignancy testing segments, plus any partnership or acquisition announcements that could unlock shareholder value.